SarcoMedUSA

[On Demand]
Search General Info
Search Education
Search Partnering Companies
SarcomedUSA, Inc. [Sarcomed] was formed in to investigate if DNase 1 could reduce the chronic pulmonary inflammation seen in sarcoidosis patients.
• The company is led by experienced biotech entrepreneurs with strong drug development backgrounds and respected expert clinical advisors.
• Clear development & regulatory pathway [Orphan status designation granted], including patent protection until 2033 [FTO Goodwin].
Comparison to Cystic Fibrosis (CF) shows substantial market potential for Sarcoidosis.
• Pulmozyme® was approved in 1994 for Cystic Fibrosis [70,000 patients worldwide] and all patents expired by 2015.
• Reported sales of $755M in 2018 and $746M in 2017.
• ~ 1.2M sarcoid patients worldwide, 50% of sarcoidosis patients require systemic therapy corticosteroids and ~ 30% exhibit chronic progressive disease.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
SM001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Sarcomedusa